| Hazard Information | Back Directory | [Uses]
Treatment of muscular dystrophy and age-related sarcopenia or frailty. | [in vivo]
Stamulumab (MYO-029; ip; 1-10 mg/kg/week for 12 weeks) increases skeletal muscle mass in vivo in a concentration-dependent manner in SCID mice. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia[1].
Stamulumab (i.v.; 1, 5, 20, 100 mg/kg/week for 4 weeks) has a central clearance (CL) of 0.25 mL/h/kg in C57/SCID mice[1].
Pharmacokinetic Parameters of Stamulumab (MYO-029)[1].
| C57/SCID mice IV (1-100 mg/kg/week for 4 weeks) | Sprague Dawley rats (2-50 mg/kg; single injection) | Cynomolgus monkeys (10-100 mg/kg/week for 5 or 39 weeks) | | CL (mL/h/kg) | 0.245 | 0.542 | 0.228 | | Volume of central compartment (mL/kg) | 103 | 58.9 | 41.8 | | Distributive clearance (mL/h/kg) | | 1.79 | 0.815 |
| Animal Model: | Female SCID mice[1] | | Dosage: | 1, 2.5, 5, 10 mg/kg | | Administration: | IP; every week for 12 weeks | | Result: | Increased skeletal muscle mass in vivo in a concentration‐dependent manner.
|
|
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
| Company Name: |
Wonda Science
|
| Tel: |
+1 (514) 581-6866 |
| Website: |
www.wondascience.com |
|